Effectiveness of Potent Antiretroviral Therapy on Time to AIDS and Death in Men With Known HIV Infection Duration
CONTEXT.— Time to development of acquired immunodeficiency syndrome (AIDS) and time to death have been extended with the increased use of combination therapy and protease inhibitors. Cohort studies following up persons with human immunodeficiency virus (HIV) infection in periods characterized by dif...
Gespeichert in:
Veröffentlicht in: | JAMA : the journal of the American Medical Association 1998-11, Vol.280 (17), p.1497-1503 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | CONTEXT.— Time to development of acquired immunodeficiency syndrome (AIDS) and
time to death have been extended with the increased use of combination therapy
and protease inhibitors. Cohort studies following up persons with human immunodeficiency
virus (HIV) infection in periods characterized by different therapies offer
the opportunity to estimate therapy effectiveness at the population level. OBJECTIVE.— To assess the effectiveness of self-reported, long-term potent antiretroviral
therapy in a cohort of 536 men whose duration of HIV infection was known (seroconverters). DESIGN.— Cohort study. The cohort was compared for time to development of AIDS
and time to death in 1984 to 1990, 1990 to 1993, 1993 to July 1995, and July
1995 to July 1997 when the major treatments were no therapy, monotherapy,
combined therapy, and potent antiretroviral therapy, respectively. Survival
analysis methods with time zero set as the date of seroconversion and incorporating
staggered entries into each period were used. Mean CD4 cell change, stratified
by infection duration, was determined for each period using a random effects
model. SETTING.— The Multicenter AIDS Cohort Study (MACS) in 4 urban areas (Baltimore,
Md; Chicago, Ill; Los Angeles, Calif; and Pittsburgh, Pa). PARTICIPANTS.— A total of 5622 men who were 18 years or older were enrolled into MACS.
Of the 5622, there were 2191 HIV-positive individuals at enrollment. Of the
3431 men who were HIV-negative, 536 were observed to seroconvert and were
followed up for up to 13 years. The group of 536 who seroconverted constituted
the study population. MAIN OUTCOME MEASURES.— Time from seroconversion to development of AIDS and to death and change
in CD4 cell count. RESULTS.— A total of 231 seroconverters developed AIDS, and 200 men died. Using
1990 to 1993 as the reference period, the relative hazard of AIDS was 1.04
(95% confidence interval [CI], 0.73-1.48) during 1993 to July 1995 and 0.35
(95% CI, 0.20-0.61) during July 1995 to July 1997. Relative hazards of death
were 0.87 (95% CI, 0.58-1.31) and 0.62 (95% CI, 0.38-1.01) for the same periods.
The relative time (the factor by which times are contracted or expanded) to
development of AIDS was 0.97 (95% CI, 0.86-1.09) for 1993 to July 1995 and
1.63 (95% CI, 1.40-1.89) for July 1995 to July 1997. Relative survival time
for 1993 to July 1995 was 1.01 (95% CI, 0.91-1.12) and for July 1995 to July
1997 was 1.21 (95% CI, 1.07-1.36) relative to 1990 to 1993. The rate of CD4
cell co |
---|---|
ISSN: | 0098-7484 1538-3598 |
DOI: | 10.1001/jama.280.17.1497 |